Nortem Biogroup (XPAR:MLBIO) ROCE % : 7.28% (As of Dec. 2022)

View and export this data going back to 2023. Start your Free Trial

What is Nortem Biogroup ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Nortem Biogroup's annualized ROCE % for the quarter that ended in Dec. 2022 was 7.28%.

Nortem Biogroup ROCE % Historical Data

The historical data trend for Nortem Biogroup's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nortem Biogroup ROCE % Chart

Nortem Biogroup Annual Data

Trend

Dec21

Dec22

ROCE %

10.82

7.28

Nortem Biogroup Semi-Annual Data
	Dec21	Dec22
ROCE %	10.82	7.28

Nortem Biogroup ROCE % Calculation

Nortem Biogroup's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	0.638	/	( ( (9.434 - 1.984)	+	(13.468 - 3.387) )	/ 2 )
	=	0.638	/	( (7.45	+	10.081)	/ 2 )
	=	0.638	/	8.7655
	=	7.28 %

Nortem Biogroup's ROCE % of for the quarter that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2022 )		(Q: Dec. 2021 )		(Q: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2022 )		(Q: Dec. 2021 )		(Q: Dec. 2022 )
	=	0.638	/	( ( (9.434 - 1.984)	+	(13.468 - 3.387) )	/ 2 )
	=	0.638	/	( ( 7.45	+	10.081 )	/ 2 )
	=	0.638	/	8.7655
	=	7.28 %

(1) Note: The EBIT data used here is one times the annual (Dec. 2022) EBIT data.

Nortem Biogroup (XPAR:MLBIO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Nortem Biogroup ROCE % Related Terms

Thank you for viewing the detailed overview of Nortem Biogroup's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nortem Biogroup (XPAR:MLBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Nortem Biogroup (XPAR:MLBIO) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Calle Alexander Humboldt 12B, Polígono Industrial Salinas de Poniente, El Puerto de Santa María, Cadiz, ESP, 11500

Website

https://www.nortembiogroup.com

Nortem Chem SA is engaged in the research, development, innovation and industrialization in the field of biochemistry and biotechnology, as well as the production and sale of products based on biochemical and/or biotechnological processes. It emerged as a biotechnological company in the field of the food and chemical industry, with maximum environmental awareness, concentrating its research and product development efforts on the development of environmentally friendly alternatives from renewable sources and obtaining its own microorganisms (Aspergillus Niger and Yarrowia lipolytica) with outstanding capabilities from adaptation and selection processes, avoiding the use of genetic modification technologies.

Nortem Biogroup (XPAR:MLBIO) Headlines

No Headlines